IR@PKUHSC  > 北京大学第二临床医学院  > 心血管内科
学科主题临床医学
Adverse events of statin-fenofibric acid versus statin monotherapy: a meta-analysis of randomized controlled trials
Geng, Qiang; Ren, Jingyi; Chen, Hong; Lee, Chongyou; Liang, Wenqing
关键词Adverse events Fenofibric acid Meta-analysis Statin
刊名CURRENT MEDICAL RESEARCH AND OPINION
2013-03-01
DOI10.1185/03007995.2013.766592
29期:3页:181-188
收录类别SCI
文章类型Article
WOS标题词Science & Technology
类目[WOS]Medicine, General & Internal ; Medicine, Research & Experimental
研究领域[WOS]General & Internal Medicine ; Research & Experimental Medicine
关键词[WOS]MIXED DYSLIPIDEMIA ; COMBINED HYPERLIPIDEMIA ; COMBINATION ; EFFICACY ; SAFETY ; SIMVASTATIN ; ROSUVASTATIN ; PARTICIPANTS ; THERAPY ; PHASE-3
英文摘要

Background:

Patients with mixed dyslipidemia can benefit from the combination of fenofibric acid (FA) with statins, but concerns about adverse events make physicians reluctant to prescribe the combination therapy.

Objective:

In the present study, we performed a meta-analysis of randomized controlled trials (RCTs) to assess the efficacy and adverse events in patients taking statins and FA.

Methods:

Medline, Embase and the Cochrane Library were searched to identify studies that reported adverse events. Finally, five trials covering 2704 patients were selected in this study.

Results:

There were significant decreases in TG and increases in HDL-C in patients receiving combination therapy compared with statin monotherapy. The incidence of hepatic toxicity (OR, 3.57; 95% CI, 1.17-10.83; P<0.05) and increased creatinine (OR, 3.22; 95% CI, 1.28-8.11; P<0.05) was significantly higher in the FA+low-dose statin group than in the corresponding statin monotherapy. The incidence of CK elevations and muscle-associated AEs was not statistically different between the two groups. The adverse events in the FA+moderate-dose statin group were almost identical to those in the FA+low-dose statin group.

Conclusions:

In conclusion, combination therapy could improve the blood lipid profile. Addition of FA to statins therapy is more frequently associated with hepatic and renal toxicity than muscle-associated AEs. Therefore patients taking the combination of FA with statins should have liver enzyme and renal function monitored. However, we still need large-scale and long follow-up period RCTs to definitively confirm the adverse events of FA-statin therapy.

语种英语
WOS记录号WOS:000314851000004
项目编号NSFC 30570712
资助机构National Natural Science Foundation of China
引用统计
被引频次:7[WOS]   [WOS记录]     [WOS相关记录]
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/64786
专题北京大学第二临床医学院_心血管内科
作者单位Peking Univ, Dept Cardiol, Peoples Hosp, Beijing 100044, Peoples R China
推荐引用方式
GB/T 7714
Geng, Qiang,Ren, Jingyi,Chen, Hong,et al. Adverse events of statin-fenofibric acid versus statin monotherapy: a meta-analysis of randomized controlled trials[J]. CURRENT MEDICAL RESEARCH AND OPINION,2013,29(3):181-188.
APA Geng, Qiang,Ren, Jingyi,Chen, Hong,Lee, Chongyou,&Liang, Wenqing.(2013).Adverse events of statin-fenofibric acid versus statin monotherapy: a meta-analysis of randomized controlled trials.CURRENT MEDICAL RESEARCH AND OPINION,29(3),181-188.
MLA Geng, Qiang,et al."Adverse events of statin-fenofibric acid versus statin monotherapy: a meta-analysis of randomized controlled trials".CURRENT MEDICAL RESEARCH AND OPINION 29.3(2013):181-188.
条目包含的文件
条目无相关文件。
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Geng, Qiang]的文章
[Ren, Jingyi]的文章
[Chen, Hong]的文章
百度学术
百度学术中相似的文章
[Geng, Qiang]的文章
[Ren, Jingyi]的文章
[Chen, Hong]的文章
必应学术
必应学术中相似的文章
[Geng, Qiang]的文章
[Ren, Jingyi]的文章
[Chen, Hong]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。